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Generation of Multiple Stable Dermcidin-Derived
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Siegbert Rieg1, Silke Seeber2, Heiko Steffen1, Andreas Humeny2, Hubert Kalbacher3, Stefan Stevanovic4,
Akihiko Kimura5, Claus Garbe1 and Birgit Schittek1
Antimicrobial peptides (AMPs) are effector molecules of innate immunity. Dermcidin (DCD), a recently
discovered AMP with broad-spectrum activity, is produced constitutively by the eccrine sweat glands and
secreted into sweat. In this study, we investigated the proteolytic processing, site-specific expression, and
stability of DCD peptides in eccrine sweat. Using surface-enhanced laser desorption ionization time-of-flight
mass spectrometry (SELDI-TOF-MS) and reversed-phase high-pressure liquid chromatography analysis, we
identified in eccrine sweat 14 proteolytically processed DCD peptides. Semiquantitative SELDI-TOF-MS analysis
indicated that processing of DCD-1L is individually different, but generates a few dominant peptides. At body
sites with a high probability for contact with pathogenic microorganisms, a high amount of antimicrobial active
DCD peptides was detected in sweat. Furthermore, we show that the secretion rate of DCD is constant during a
period of prolonged sweating and that DCD peptides are stable in sweat over several hours. Other known AMPs
like the human cathelicidin LL-37 and a- or b-defensins were not detected in significant quantity in eccrine
sweat. Owing to the durable and abundant presence, DCD-derived peptides contribute to the first line of
defense by building a constant barrier that overlies the epithelial skin.
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INTRODUCTION
Epithelia of multicellular organisms are continuously exposed to
a large number of microorganisms. The remarkable resistance
to infection indicates effective defense mechanisms along the
epithelial barriers. Within this first line of defense, antimicrobial
peptides (AMPs) are emerging as important effector molecules.
In mammalian skin, AMPs are produced by cells within
the epithelial lining, are delivered by circulating cells, or are
produced by adjacent cells of the epithelial appendages. In
human skin, keratinocytes are a major source of antimicrobial
active peptides or larger proteins. Whereas the ribonuclease
RNase 7 (Harder and Schroder, 2002), psoriasin (S100A7)
(Glaser et al., 2005), and secretory leukoprotease inhibitor
(Wiedow et al., 1998) are produced constitutively by keratino-
cytes, the human cathelicidin LL-37 (Frohm et al., 1997) and the
b-defensin-2 (HBD-2) and -3 (HBD-3) (Harder et al., 1997, 2001)
are induced in keratinocytes under inflammatory conditions.
We recently discovered a new AMP named dermcidin
(DCD) with a broad spectrum of activity and no homology to
other known AMPs (Schittek et al., 2001). DCD is expressed
in the eccrine sweat glands, secreted into sweat, and
transported via sweat to the epidermal surface. In contrast
to other AMPs such as human cathelicidin LL-37 and the
human b-defensins, DCD is not induced in epidermal
keratinocytes under inflammatory skin conditions like atopic
dermatitis, psoriasis, or lichen planus, but is constitutively
produced by the eccrine sweat glands (Rieg et al., 2004).
Thus, DCD takes part in the constitutive innate defense of
human skin. Recently, we showed that patients with atopic
dermatitis have a reduced amount of DCD peptides in sweat,
which correlated with diminished antimicrobial activity of
eccrine sweat in vivo (Rieg et al., 2005).
Analogous to other known AMPs, a precursor protein of
DCD is produced, which is proteolytically processed to
generate antimicrobial active DCD peptides. The DCD-
precursor protein consists of 110-amino-acid residues with a
19-amino-acid N-terminal signal peptide (Schittek et al.,
2001). Antimicrobial active DCD peptides are derived from
the C-terminal region of the precursor protein, DCD-1L
(consisting of 48 amino acids) and DCD-1 (47 amino acids,
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lacking the last leucine). Both peptides show antimicrobial
activity against a variety of pathogenic microorganisms
including Staphylococcus aureus, E. coli, Entercoccus faeca-
lis, and Candida albicans under in vitro conditions resem-
bling human sweat. In human sweat, 1–10 mg/ml of DCD-1 is
found, a concentration that is toxic to most microorganisms
tested (Schittek et al., 2001; Flad et al., 2002). Using surface-
enhanced laser desorption ionization time-of-flight mass
spectrometry (SELDI-TOF-MS) technology, we described that
besides these peptides, shorter peptides with 43–46 amino
acids could be identified in eccrine sweat (Flad et al., 2002).
In this study, we investigated (a) the spectrum of
proteolytically processed DCD peptides and (b) the presence
of other AMPs like human defensins and the human
cathelicidin LL-37 in eccrine sweat of healthy volunteers
using reversed-phase high-pressure liquid chromatography
(RP-HPLC) and SELDI-TOF-MS. Furthermore, we analyzed
whether (a) the amount of DCD peptides in sweat differs
between several body sites, (b) the rate of DCD secretion
remains constant over time, (c) whether DCD peptides are
stable in sweat, and (d) whether DCD-derived peptides are
present in tears, saliva, and nasal secretions.
RESULTS
Several DCD-derived peptides are present in human sweat
Using SELDI-TOF-MS, we previously identified in human
sweat from healthy persons five proteolytically processed
peptides derived from the full-length DCD protein sequence
(Schittek et al., 2001; Flad et al., 2002). Among those are the
peptides DCD-1L (48mer) and DCD-1 (47mer), which are
antimicrobially active on different microorganisms.
To get the spectrum of all possible processed DCD
peptides in sweat, we performed SELDI-TOF-MS analysis of
physical-exercise-induced sweat of the forehead of 18 healthy
volunteers (Figure 1). In addition, we separated sweat of four
healthy volunteers by RP-HPLC and performed from the
collected fractions mass spectrometry and Edman sequencing
as described earlier (Figure 2) (Schittek et al., 2001). In
Table 1, all identified processed DCD-derived peptides are
summarized. We identified 13 different DCD peptides derived
from the C-terminal end and one N-terminal-derived peptide
named YDP-42 and its dimeric form. DCD-1 (pos. 63–109)
and SSL-46 have lost the last leucine or valine residue,
respectively, compared to the parental peptide DCD-1L and
SSL-45 has in addition lost the serine. SSL-29 and SSL-25 are
shorter peptides and have the same N-terminus as DCD-1L,
beginning with SSL. The other peptides lack the first three
amino acids SSL from DCD-1L, beginning with the amino
acids LEK, and are either 41–45 amino acids long (LEK-41 and
LEK-45) or only 24 or 26 amino acids long (LEK-24 and LEK-
26). Interestingly, nine of the 13 C-terminal-derived DCD
peptides are anionic, two peptides have a neutral charge and
two shorter peptides – SSL-25 and LEK-24 – are cationic.
LL-37 and defensins are not expressed in significant quantity
in eccrine sweat
It has been described that the AMP LL-37 and truncated forms
of this peptide are present in sweat (Murakami et al., 2002,
2004). To analyze whether LL-37 and other known AMPs or
proteins like a- and b-defensins and lysozyme are present in
sweat, we performed SELDI-TOF-MS from sweat samples
from 18 healthy volunteers and in parallel separated eccrine
sweat by RP-HPLC and performed antimicrobial assays from
the fractions. From antimicrobial active and nonactive
fractions, we performed mass spectrometry and Edman
sequencing. Using both methods besides DCD peptides, we
could not detect other known AMPs in sweat in significant
quantity (Figures 1 and 2). Neither LL-37 (4,493.3 Da) nor the
derivatives KR-20 (2,468.9 Da), RK-31 (3,800.5 Da), and
KS-30 (3,644.3 Da) as well as the b-defensins HBD-1
(3,928.6 Da), HBD-2 (4,328.2 Da), HBD-3 (5,155.2 Da), or
a-defensins HNP-1 (3,442.1 Da), HNP-2 (3,371.0 Da), and
HNP-3 (3,486.1 Da) are present in eccrine sweat. As the
above-mentioned cathelicidins and defensins are cationic
peptides, we carried out additional SELDI-TOF-MS analysis
with a cation exchange chip (WCX2). In accordance with
measurements with a reversed-phase chip (H4), none of the
above-mentioned cationic AMPs could be detected (Figure
3a). Furthermore, to rule out a weak affinity of human
cathelicidin, a- or b-defensins to the reversed-phase chip, we
analyzed synthetic LL-37, HNP-2, and HBD-1 peptides on a
reversed-phase chip. Synthetic LL-37 could be identified
when added to eccrine sweat samples that did not contain
LL-37-corresponding masses in previous analyses in concen-
trations as low as 2 mM (Figure 3b). In SELDI analyses of sweat
with low amounts of DCD-derived peaks in the molecular
weight range of 4,493 Da, LL-37 can still be detected in a
concentration of 1.1 mM (Figure 3b). Accordingly, HNP-1/-2
and HBD-1 were detected in concentrations of 2.9 and
2.5 mM, respectively (Figure 3c); HBD-2 was detected in a
concentration of 2.3mM (Figure 3d). Furthermore, using
Western blot analysis, the a-defensins HNP-1, HNP-2, and
HNP-3, b-defensin HBD-2 or lysozyme could not be detected
in eccrine sweat, whereas DCD was readily detectable
(Figure 3e). Considering the sensitivity of our Western blot
analysis, we conclude that the defensins are either absent
from eccrine sweat or present at concentrations lower than
2 mM. These results indicate that DCD-derived peptides are
the predominant AMPs in sweat, and that neither defensins
nor LL-37 are present in significant quantity, that is,
antimicrobial active quantity, in sweat.
Processing of DCD-1L is individually different, but generates
a few dominant peptides
SELDI analysis of sweat of 18 healthy persons indicates an
individual proteolytic pattern of DCD-derived peptides in
sweat (Figure 1). Interestingly, in most individuals, we
identified the DCD peptides DCD-1L (15 of 18), DCD-1 (13
of 18), SSL-46 (14 of 18), LEK-45 (18 of 18), LEK-44 (12 of
18), LEK-43 (14 of 18), and the shorter DCD peptides that
have either a neutral charge or are cationic: SSL-29 (16 of 18)
and SSL-25 (11 of 18), respectively (Table 2). Among those, at
least one of the most prominent ones, DCD-1L, LEK-45, or
SSL-29, is always present.
Despite these dominant peptides in most sweat samples,
there are individual differences in the amount of each peptide
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as well as the proteolytic pattern. Whereas in most
individuals (13 volunteers), seven to nine C-terminal-derived
DCD peptides are present in sweat, in a few individuals (five
persons) only four to five DCD-derived peptides could be
identified in sweat. Irrespective of the number of total
processed peptides, most individuals have two to four major
DCD-processed peptides in sweat (Table 2). This indicates
that each individual processes the DCD peptides differently,
but that there are prominent peptides such as DCD-1L, DCD-
1, SSL-46, SSL-29, SSL-25 and LEK-45 that are present in the
majority of sweat samples analyzed.
The amount of DCD-derived peptides in sweat is dependent
on the body site
To analyze whether there are differences in the amount of
DCD-derived peptides secreted into sweat at various body
sites, we performed semiquantitative analysis of DCD
peptides in the sweat of healthy subjects using SELDI-TOF-
MS. Sweat samples collected from various body sites of five
healthy volunteers were applied together with 100 fmol of
bovine insulin (MW 5,733.6 Da) on a reversed-phase (H4)
Protein Chip Array (Ciphergen Biosystems, Freemont, CA).
The spectra were analyzed by Protein Chip Software 3.1
(Ciphergen Biosystems, Freemont, CA). After baseline sub-
traction, all spectra were normalized to the bovine insulin
peak for semiquantification of the DCD-derived peptides. As
can be seen in Figure 4, the amount of DCD-derived peptides
is different at the various body sites. Whereas at the thorax
and legs relatively low levels of DCD peptides are present in
eccrine sweat, on the face, arms, and especially in the palms,
the amount of DCD peptides in sweat is high. In the region of
the axilla, where in contrast to the other analyzed body sites
sweat is secreted predominantly, but not exclusively by
apocrine sweat glands, the amount of DCD peptides is also
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Figure 1. Spectra of SELDI-TOF-MS-analysis of human sweat of 10 healthy volunteers using a reversed-phase (H4) protein chip. These spectra are
representative of the SELDI-TOF-MS analysis of overall 18 analyzed sweat samples. Shown are masses from 2,000 to 6,000 Da. After baseline subtraction,
spectra were normalized to the bovine insulin peak (5,733.6 Da). From the masses, several DCD-derived peptides could be identified (summarized in Table 1).
The deviation of the masses measured in the SELDI-TOF-MS analyses to the theoretical masses listed in Table 1 is around 71.5 Da in the mass ranges
3,000–5,000 Da and around 73 Da in the mass ranges 2,000–3,000 Da.
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low (data not shown). This reflects the fact that DCD is only
expressed in eccrine sweat glands and not in apocrine sweat
glands (Schittek et al., 2001; Minami et al., 2004). These
results imply that at body sites with a high probability for a
contact with pathogens (palms, face, arms), a pronounced
amount of antimicrobial DCD peptides is secreted into sweat.
DCD is secreted into sweat at a constant rate
Next, we asked whether the secretion rate of DCD into sweat
changes over time. Therefore, we collected sweat from five
volunteers at different time points during a prolonged episode
of sweating – immediately at the beginning and 20 and
40 minutes afterwards – and performed a semiquantification
using SELDI-TOF-MS. Figure 5 shows that the amount of
DCD-derived peptides in sweat does not appreciably change
during a sweating period of 40 minutes. This indicates that
the secretion rate of DCD keeps constant over time.
DCD-derived peptides are stable in sweat
Are DCD peptides rapidly destroyed by proteases in sweat or
are they stable? To answer this question, we collected native
sweat and kept it at room temperature up to 72 hours. Sweat
samples were evaluated by Western blot using the mono-
clonal G-81 antibody, which recognizes all C-terminal-derived
DCD peptides. After incubation of sweat for 24, 48, and up to
72 hours, C-terminal DCD peptides were still detected by
Western blot (Figure 6a). Moreover, SELDI-TOF-MS analysis
of eccrine sweat after 4, 16, and 40 hours of incubation at
room temperature revealed mass profiles still containing
prominent DCD peaks after 16 and 40 hours of incubation,
yet a slow but continuous shift towards the processed DCD
peptides LEK-43, LEK-42, LEK-41, and SSL-29 can be
observed (Figure 6b). These results indicate that DCD
peptides in sweat are relatively stable.
DCD peptides are not present in nasal secretion, tears, and
saliva
Next, we analyzed whether DCD-derived peptides are
present in other body fluids like nasal secretions, tears, and
saliva. As can be seen in Figure 7, DCD peptides are not
present in these body fluids, whereas the a-defensins HNP-1,
HNP-2, and HNP-3 are present in saliva and to a lesser extent
in tears. Other AMPs like b-defensins and LL-37 were not
detected by SELDI-TOF-MS analysis in tears, nasal fluid, and
saliva. As the sensitivity of the SELDI-TOF-MS method for the
detection of b-defensins and LL-37 is in the range of 2 mM (see
above), these peptides are either absent or present at
concentrations lower than 2 mM in these body fluids analyzed
ex vivo. Lysozyme was present in all analyzed body fluids,
except sweat (data not shown and see Figure 3e).
DISCUSSION
The eccrine sweat gland is one of the major cutaneous
appendages with approximately 2–4 million glands that are
distributed over nearly the entire body surface (Sato et al.,
1989). For long, only its role in thermoregulation was
appreciated. Recently, DCD, a novel human AMP, was
described as being a major constituent of eccrine sweat,
thereby indicating that the eccrine apparatus is capable of
functioning as an effector organ in the first line of defense of
human skin. In our present investigation, we analyzed the
proteolytic processing of DCD in eccrine sweat. Furthermore,
we examined site-specific DCD expression as well as the
kinetics of secretion and degradation of DCD peptides in
eccrine sweat. Additionally, we addressed the question of
whether other AMPs are present in significant amounts in
human eccrine sweat.
Using SELDI-TOF-MS analysis and RP-HPLC fractionation,
we detected 14 DCD-derived peptides in eccrine sweat, 13
peptides of the C-terminus, and one peptide of the
N-terminus of the full-length DCD sequence. Of the different
truncated peptides, DCD-1L, DCD-1, SSL-46, LEK-45, LEK-44,
LEK-43, and SSL-29 were found in at least two-thirds of all
individuals. Our analysis revealed an average of seven
different DCD-derived peptides (ranging from 4 to 10 DCD
peptides) in eccrine sweat of healthy volunteers. Thus, by
postsecretory proteolytic processing, the DCD gene product
gives rise to a whole group of truncated DCD peptides with
different biochemical properties and yet unknown functional
activities.
DCD-1L and DCD-1 exhibit antimicrobial activity against
Gram-positive organisms including S. aureus, E. faecalis, and
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Figure 2. RP-HPLC analysis of eccrine human sweat (spectrum of a single
healthy volunteer representative of four). Among other coeluted proteins
in some fractions, we identified in fractions 1–6 by mass spectrometry and
Edman microsequencing 1 DCD-1L, 2 DCD-1, 3 SSL-46 and LEK-44,
4 LEK-43, 5 LEK-44 and SSL-25, and 6 YDP-42. Fractions 1–3 and 5 are
antimicrobially active against S. aureus. The antimicrobial activity of these
fractions correlates well with the activity of the corresponding synthetic
peptides to S. aureus (see Schittek et al., 2001; Rieg et al., 2005).
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Gram-negative organisms including E. coli (Schittek et al.,
2001). Further investigations revealed an extended anti-
microbial spectrum including S. epidermidis (Vuong et al.,
2004), Pseudomonas putida, methicillin-resistant S. aureus,
as well as rifampicin- and isoniazid-resistant Mycobacterium
tuberculosis (Lai et al., 2005). Additionally, shorter DCD
fragments like SSL-46 (amino-acid positions 63–108) (Rieg
et al., 2005) and SSL-25 exhibit antimicrobial activity (data
not shown). Thus, analogous to the processing of other
human AMPs like cathelicidin LL-37, proteolytically derived
peptides exhibiting antimicrobial activity originate from the
C-terminus of the full-length DCD peptide. Interestingly,
proteolytically processed DCD peptides possess net charges
between 2 and þ2; thus, initially, anionic DCD-1L and
DCD-1 are the source of the generation of neutral or cationic
shorter DCD fragments due to subsequent processing.
Whether the alteration from anionic to cationic peptides
leads to a different antimicrobial spectrum and additional
functional activities or is part of the inactivation of DCD
peptides is subject to current investigations.
Proteolytic processing of DCD peptides and other sweat-
derived peptides and proteins may principally be due to host
proteases, which can be keratinocyte-derived (Komatsu et al.,
2003) or are produced by eccrine sweat glands. In eccrine
sweat, diverse proteases have been described, among these
kallikrein and kininase II (Fraki et al., 1970; Hibino et al.,
1994), acid proteases resembling cathepsin B1 and cathepsin
D (Fraki, 1976), and matrix metalloproteinase 19 (Sadowski
et al., 2003). Recent evidence suggests that the sweat-derived
aspartate protease cathepsin D and a 1,10-phenanthroline
sensitive carboxypeptidase (together with a yet unidentified
endopeptidase) are involved in the postsecretory processing
of DCD (Baechle et al., submitted). Furthermore, proteases
derived from sebaceous glands may contribute to the
degradation of AMPs on the skin surface (Frohlich et al.,
1995; Komatsu et al., 2003). It is noteworthy that the
expression of the keratinocyte-derived matrix metalloprotein-
ase 19 is upregulated under inflammatory conditions; there-
fore, the host is capable of modulating the proteolytic
capacity on the outermost surface (Sadowski et al., 2003).
Table 1. DCD-derived peptides identified in human sweat
Name Amino-acid positions/amino-acid sequence Theor. mass (Da) pI Charge
DCD-1L 63–110
SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL
4,818.5 5.07 2
DCD-1 63–109
SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV
4,705.3 5.07 2
SSL-46 63–108
SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDS
4,606.2 5.07 2
SSL-45 63–107
SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLD
4,519.1 5.15 2
SSL-29 63–91
SSLLEKGLDGAKKAVGGLGKLGKDAVEDL
2,869.3 5.97 0
SSL-25 63–87
SSLLEKGLDGAKKAVGGLGKLGKDA
2,412.8 9.40 +2
LEK-45 66–110
LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL
4,531.2 5.08 2
LEK-44 66–109
LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV
4,418.0 5.08 2
LEK-43 66–108
LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDS
4,318.9 5.08 2
LEK-42 66–107
LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLD
4,231.8 5.15 2
LEK-41 66–106
LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVL
4,116.3 5.62 1
LEK-26 66–91
LEKGLDGAKKAVGGLGKLGKDAVEDL
2,582.0 6.24 0
LEK-24 66–89
LEKGLDGAKKAVGGLGKLGKDAVE
2,353.7 8.38 +1
YDP-42 20–61
YDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQR
4,302.6/8,605.2 5.62 1
The sequence of full-length DCD is: MRFMTLLFLTALAGALVCAYDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQR SSLLEKGLDGAKKAV
GGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL
DCD-1L (amino-acid positions 63–110) is marked in bold, and the signal peptide (amino-acid positions 1–19) is marked in italics.
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Figure 3. LL-37 and defensins are not present in significant quantity in eccrine sweat. (a) Spectra of SELDI-TOF-MS analysis of eccrine human sweat using a
cation exchange (WCX2) protein chip: corresponding masses of the cationic AMPs LL-37, its derivates, or a- or b-defensins are not detected. (b) Spectra of SELDI-
TOF-MS analysis of synthetic LL-37 spiked into sweat samples using a reversed-phase (H4) protein chip: LL-37 (4,493.3 Da) is marked with an arrow and is
clearly detectable at a concentration of 20 and 2mM (first two panels). When LL-37 is spiked into sweat with low amounts of DCD-derived peaks in the molecular
weight range of 4493 Da, LL-37 can still be detected in a concentration of 1.1 mM (bottom two panels). (c and d) Spectra of SELDI-TOF-MS analysis of (c) a mix of
a-defensins HNP-1 (3,442.1 Da) and HNP-2 (3,371.0 Da) or (d) b-defensins HBD-1 (3,928.6 Da) and HBD-2 (4,328.2 Da) spiked in sweat using a reversed-phase
(H4) protein chip. The defensins are marked with an arrow and are clearly detectable at a concentration ofB2 mM. (e) Western blot analysis of 15ml of human
eccrine sweat (lanes 1 and 2 in the first three panels and lanes 2 and 3 in the last panel) with antibodies against dermcidin (G-81), a-defensins (HNPs), b-defensin
2 (HBD-2), or lysozyme. As positive controls, we used the respective synthetic peptides (lane 3: each 100 ng; lane 4: 500 ng total peptide) in the first three panels
and in the last panel 15 ml saliva (lane 1) for the detection of lysozyme. From these data, we conclude that the a- and b-defensins and lysozyme are either not
present in eccrine human sweat or present at amounts lower than 2 mM.
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Apart from host proteases, processing of DCD and potentially
other AMPs in eccrine sweat may be due to microbial-
derived proteases. Recently, degradation of human cathe-
licidin LL-37 by the S. aureus-derived metalloproteinase
aureolysin and the glutamylendopeptidase V8 protease was
described (Sieprawska-Lupa et al., 2004). Accordingly,
P. aeruginosa elastase, E. faecalis gelatinase, or P. mirabilis
metalloprotease are able to degrade and inactivate LL-37.
Interestingly, besides antimicrobial DCD-derived peptides
and proteases, which generate shortened DCD fragments,
eccrine sweat additionally contains protease inhibitors such
as cystatin A (Zeeuwen et al., 2001). It is tempting to
speculate whether these protease inhibitors play a role in the
protection of proteolytic degradation of sweat-derived
proteins and peptides by inhibition of either host- or
microbial-derived proteases.
Expression of a second AMP in eccrine sweat was
described recently. The human cathelicidin LL-37 was
detected by Western blot analysis in eccrine sweat in
concentrations of 0.1 mM (Murakami et al., 2002). In our
investigation using SELDI-TOF-MS and RP-HPLC analysis
followed by mass spectrometry and Edman sequencing, we
could not detect the human cathelicidin LL-37, shortened LL-
37-derivates, or the unprocessed precursor protein. Whereas
Murakami et al. (2002, 2004) analyzed concentrated sweat
(20:1 or 50:1) by Western blot analysis or RP-HPLC for the
detection of LL-37 peptides, we used crude sweat samples for
SELDI-TOF-MS analysis. To rule out a weak affinity of LL-37
to the reversed-phase chip, we analyzed synthetic LL-37
peptide spiked in sweat with the same protocol. Using this
approach, synthetic LL-37 could clearly be detected in
concentrations as low as 2 mM, the concentration required
for antimicrobial activity of LL-37. The same experiments
were performed for the a- and b-defensins, with similar
results. As human a- and b-defensins and LL-37 are cationic
peptides, we completed our experiments with the use of a
cation exchange chip. Consistent with the results of the
reversed-phase chip, none of these AMPs was detectable in
eccrine sweat. Furthermore, we confirmed our results using
Western blot analysis of human sweat for the a- and
b-defensins and lysozyme. The data indicated that these
peptides/proteins are either absent in eccrine sweat or present
at amounts lower than 2 mM. In previous studies, expression of
b-defensins HBD-1 and HBD-2 in eccrine sweat glands was
described by in situ hybridization and immunohistochemistry
(Fulton et al., 1997; Ali et al., 2001; Rieg et al., 2004);
however, these peptides have not been identified in human
sweat until now. In summary, we could not isolate other
AMPs in several independent experiments and with different
methods, and therefore conclude that in human sweat
isolated ex vivo DCD-derived peptides are the main AMPs
that are present in significant functional amounts.
Our results reveal a constant DCD secretion during
40 minutes of thermally induced sweating. This indicates a
durable secretion of DCD in eccrine sweat, which is not
subject to rapid exhaustion in periods of prolonged sweating.
Additionally, we show that – despite further proteolytic
processing generating shorter DCD derivates – DCD-derived
peptides are still present 72 hours after incubation at room
temperature. This indicates that DCD-derived peptides are
relatively stable in sweat. Our findings are in accordance
with previous reports of Sagawa et al., which managed to
detect DCD-derived peptides by ELISA (for medicolegal
aspects) in aged sweat for up to 11 weeks (Sagawa et al.,
2003). Even in the absence of macroscopic sweating, a daily
amount of B200 ml eccrine sweat is perspirated. Thus, a
Table 2. DCD-derived peptides identified in human sweat of 18 individuals
Individual/
DCD peptide 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Percentage of
individuals
(numbers with
peptide)
DCD-1L X X X X X X X X X X X X X X X 83% (15/18)
DCD-1 X X X X X X X X X X X X X X 78% (14/18)
SSL-46 X X X X X X X X X X X X X X 78% (14/18)
SSL-45 X X X X X X 33% (6/18)
LEK-45 X X X X X X X X X X X X X X X X X X 100% (18/18)
LEK-44 X X X X X X X X X X X X 67% (12/18)
LEK-43 X X X X X X X X X X X X X X 78% (14/18)
LEK-42 X 6% (1/18)
LEK-41 X 6% (1/18)
SSL-29 X X X X X X X X X X X X X X X X 89% (16/18)
SSL-25 X X X X X X X X X X X 61% (11/18)
LEK-26 X X X X X X X 38% (7/18)
LEK-24 X X X X 22% (4/18)
DCD-29 and LEK-26 have a neutral charge, and SSL-25 and LEK-24 are cationic peptides. The other peptides are anionic. Marked in bold are peptides that
are predominantly present in the sweat sample of the individual.
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constitutive antimicrobial barrier overlying the epithelial
sheets of the skin is secured by constant baseline DCD
sweating, by durable DCD secretion when intense sweating
occurs and by the continuous presence of DCD-derived
peptides owing to proteolytic processing, which occurs with
moderate to low kinetics.
Site-specific expression of AMPs has been described for
HBD-1 and HBD-2, with pronounced expression in plantar
skin and in the scalp (Ali et al., 2001). Accordingly, the newly
described AMP psoriasin (S100A7) can be detected in highest
concentrations on the skin surface of face, scalp, palms, and
soles (Glaser et al., 2005). We here demonstrate regional
differences in the concentration of DCD-derived peptides in
eccrine sweat with the highest amounts of DCD peptides in
the sweat of palms, arms, and forehead. Taken together with
the fact that the density of the eccrine sweat glands is highest
at the palms, soles, and face, our results underline observa-
tions of site-specific expression of AMPs with pronounced
DCD secretion in body areas, which are most often exposed
to pathogens and minor trauma.
In conclusion, our results indicate that DCD is the
predominant AMP expressed in eccrine sweat. Multiple
DCD-derived peptides are generated by proteolytic proces-
sing, confirming the concept that human eccrine sweat
represents a suitable and efficient vehicle to deliver innate
defense molecules onto the skin surface. Through the
continuous and abundant presence of DCD peptides in
sweat, a constitutive first line of defense is established, which
overlies the epithelial barrier of the skin.
MATERIALS AND METHODS
Collection of sweat, tears, saliva, and nasal secretions
For SELDI-TOF-MS analysis of the proteolytic pattern of DCD
peptides, eccrine sweat was collected from 18 healthy volunteers
(seven women and 11 men, mean age 28.0 years, without skin or
systemic diseases, who were on no systemic medications, except for
two women on oral contraceptives, five volunteers were smokers)
after sweat induction by physical exercise on a bicycle ergometer.
For each participant, 5ml of the initial portion of sweat of the
forehead was collected and frozen immediately at 201C until
analysis. Participants were asked not to wash or apply ointments
6 hours prior to the investigation. For the analysis of body site-
specific differences and DCD secretion over time, sweating was
thermally induced by sauna visits. Of five healthy individuals (two
women and three men, mean age 29.4 years), sweat samples were
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Figure 4. SELDI-TOF-MS-analysis of eccrine sweat collected from different
body sites: (a) forehead, (b) thorax, (c) arms, (d) legs, and (e) palms. Shown
are masses from 2,000 to 6,000 Da. After baseline subtraction, spectra were
normalized to the bovine insulin peak (5,733.6 Da). Spectra shown are from
sweat of a single healthy volunteer representative of five.
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Figure 5. SELDI-TOF-MS-analysis of eccrine sweat collected at different
time points during a prolonged period of sweating. Sweat was collected at
the beginning, time (a) 0, (b) 20 minutes afterwards, and (c) 40 minutes after
the beginning of sweating. Spectra shown are from sweat of a single healthy
volunteer representative of five.
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taken at respective body sites (palmar sweat could only be obtained
from two volunteers) and at three different time points (initial portion
of sweat of the forehead, after 20 and 40 minutes). Sweat was
incubated at room temperature for up to 40 hours to analyze the
kinetics of proteolytic degradation of DCD by RP-HPLC analysis
and SELDI-TOF-MS. Saliva and nasal secretions of five healthy
individuals were collected and frozen immediately at 201C.
Sampling of tears was carried out with the help of sliced onions,
and tears were also immediately frozen at 201C. The ethics
committee of the medical faculty of Tu¨bingen University approved
all described studies, and participants gave written, informed
consent. The study was conducted according to the Declaration of
Helsinki Principles.
Semiquantitative SELDI analysis of sweat, nasal secretions,
tears, and saliva
The sweat samples were analyzed on a reversed-phase (H4) or a
weak cation exchange (WCX2) Protein Chip Array (Ciphergen
Biosystems, Freemont, CA). Sweat samples were centrifuged
1 minute at 13,000 r.p.m. (16,000 g) to remove particles or debris,
but were not sterile filtered. For reversed-phase (H4) analysis, 1 ml of
the supernatant was added to 4ml 50 mM sodium phosphate buffer
(pH 6.5). Protein Chip Arrays were pretreated with 3 ml of 50% (vol/
vol) acetonitrile/water for 1 minute, and after 2 minutes of drying,
1ml of the diluted sweat solution was added. After drying (8 minutes),
spots were washed four times with 3 ml H2O (by flushing each spot
three times) and air-dried. For SELDI analysis with a weak cation
exchange chip (WCX2), 1ml of the supernatant was added to 4 ml of
50 mM sodium acetate, pH 4.0 (binding buffer). Protein Chip Arrays
were equilibrated for 5 minutes with 3ml of 50 mM sodium acetate
(pH 4.0), and then the binding buffer was replaced by 1 ml of the
diluted sweat sample. After 30 minutes of incubation in a humidity
chamber, spots were washed three times with 3 ml of the binding
buffer and once with 3ml H2O, and air-dried.
After drying 1 ml of matrix consisting of a saturated solution of
sinapinic acid in 50% acetonitrile/water (vol/vol), 0.5% trifluoracetic
acid with 100 fmol/ml bovine insulin (MW 5,733.6 Da) was added.
SELDI-TOF-MS analysis of each sweat sample was performed in
triplicate. Chips were read with the following instrument settings:
laser intensity 230, detector sensitivity 8, detector voltage 19.7 kV,
and positions 18–78 were read with an increment of 5, resulting in
12 different spot positions. Ten laser shots were collected on each
position (total shots collected and averaged: 120/sample), and two
warming shots were fired at each position, which were not included
in the collection. The acquired mass range for the detection of DCD
peptides included 0–12,500 Da with a focus mass at 4,800 Da.
Furthermore, we performed several SELDI analyses from the
respective samples in which we focused on different molecular
weight ranges, from 0 to 12,500 Da with a focus mass at 4,800 or
10,000 Da and from 10–25 kDa with a focus mass at 19 kDa.
Concentrating on molecular masses between 10 and 16 kDa, we
detected lysozyme, using SELDI-TOF-MS in tears, nasal secretions,
and saliva, but not in human sweat. Calibration was carried out with
the bovine insulin peak (MW 5,733.6 Da). The spectra were
analyzed by Protein Chip Software 3.1 (Ciphergen Biosystems,
Freemont, CA). After baseline subtraction, all spectra were normal-
ized to the internally obtained bovine insulin peak for semiquanti-
fication. We did provide evidence that the semiquantification of
DCD peptides using SELDI-TOF-MS is adequate since the results are
in accordance with the data we achieved with ELISA analysis of
human sweat (Rieg et al., 2005). Previous analyses revealed a high
sensitivity of the SELDI-TOF-MS analysis with the detection of
synthetic DCD-1 peptide by SELDI-TOF-MS in concentrations as low
as 0.27mM (Flad et al., 2002). Samples of the other body fluids were
analyzed accordingly, using the reversed-phase chip (H4).
HPLC analysis of eccrine sweat
Crude sweat was centrifuged 5 minutes at 13,000 r.p.m.
(16,000 g). Eight hundred microliters of the supernatant was
applied to an RP-HPLC on a Nucleosil C18 column (150 10 mm)
with 7mm particles and a 100-A˚ pore size with a flow rate of 2.5 ml/
minute. Solvent A was 0.055% aqueous trifluoroacetic acid and
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Figure 6. Stability of DCD-derived peptides in eccrine sweat. (a) Western
blot analysis of eccrine human sweat after incubation periods of 0, 24, 48,
and 72 hours at room temperature using the monoclonal antibody G-81,
which recognizes C-terminal-derived DCD-peptides. DCD peptides were still
detected in sweat after incubation of up to 72 hours at room temperature.
Detection of human albumin (MW 67 kDa) was used as a loading control. (b)
SELDI-TOF-MS analysis of native human sweat after incubation periods of 0,
4, 16, and 40 hours at room temperature using a reversed-phase (H4) protein
chip. After baseline subtraction, spectra were normalized to the bovine
insulin peak (5,733.6 Da). DCD peptides are still detectable after 40 hours of
incubation at room temperature, yet a slow but continuous shift towards the
processed DCD peptides LEK-43, LEK-42, LEK-41, and SSL-29 can be
observed.
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solvent B was 80% acetonitrile in 0.05% aqueous trifluoroacetic
acid. A linear gradient of 5% B to 80% B over 40 minutes was used.
The resulting elution peaks were collected and lyophilized. DCD-
derived peptides were identified by matrix-assisted laser desorption ioni-
zation time of flight (MALDI-TOF) analysis (G2025A, Hewlett-Packard,
Waldbronn, Germany) and N-terminal Edman microsequencing
with an Applied Biosystems 494 protein sequencer (Applied
Biosystems, Weiterstadt, Germany).
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Figure 7. Spectra of SELDI-TOF-MS analysis of (a) tears, (b) nasal fluid, and (c) saliva from three healthy volunteers. The a-defensins HNP-1 (3,442.1 Da),
HNP-2 (3,371.0 Da), and HNP-3 (3,486.1 Da) are marked in a box. Shown are masses from 2,000 to 6,000 Da. After baseline subtraction, spectra were
normalized to the bovine insulin peak (5,733.6 Da).
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Western blot analysis of eccrine sweat
After physical exercise, sweat of the forehead was collected and
analyzed by Western blot. Sweat was centrifuged 3 minutes at
13,000 r.p.m. (16,000 g) to remove particles and frozen either
immediately (0 hour) or after incubation at room temperature (24,
48, and 72 hours). Fifteen microliters of the samples were separated
by SDS-PAGE (using 15% acrylamide with 0.05% bisacrylamide),
transferred electrophoretically (1,200 mA/h) onto polyvinylidene
difluoride membrane sheets (Immobilon-PSQ, Millipore, Germany)
with a tank type blotter, and then blocked in 10% nonfat milk in PBS
(pH 7.4) for 30 minutes at room temperature. After incubation with
the primary antibodies overnight at 41C, the membrane sheets were
washed with phosphate buffer and incubated with the respective
secondary biotin-conjugated polyclonal antibodies (1:1,500 in
blocking solution). After washing in phosphate buffer, the strepta-
vidin–AP conjugate (Roche, Mannheim, Germany) was used for the
detection of biotin-labeled secondary antibody. The membrane was
immersed in CDP-Star solution (Western Lightning Chemilumines-
cence Reagents for AP; Roche, Mannheim, Germany) for 10 minutes,
and then exposed to X-ray film (Eastman Kodak, Rochester, NY).
Western blot analysis was performed using the following primary
antibodies: monoclonal mouse anti-DCD antibody (G-81; 1:2,000 in
blocking solution; Sagawa et al., 2003), rabbit anti-HNPs polyclonal
antiserum (1:1,000 dilution, kindly provided by H Kalbacher,
Tu¨bingen, Germany), goat anti-human HBD-2 polyclonal antiserum
(1:1,000 dilution, Cell Concepts, Umkirch, Germany), mouse anti-
human lysozyme monoclonal antibody (1:200 dilution in 4% BSA in
phosphate buffer; Acris, Hiddenhausen, Germany), and mouse anti-
human albumin monoclonal antibody (1:1,000 dilution; Sigma). The
peptides LL-37, DCD-1L, and a- and b-defensins were either purchased
from Sigma or kindly provided by H Kalbacher (Tu¨bingen, Germany).
Antimicrobial assays
Antimicrobial assays were performed using the colony-forming units
(CFU) assay as described previously (Rieg et al., 2005). S. aureus
(ATCC 25923) cultures were grown to mid-exponential growth
phase and washed twice with 10 mM sodium phosphate buffer (pH
7.0). Bacterial concentration was estimated photometrically at
600 nm. Absorbance of 1.0 corresponded to 1.97 107 cells of
S. aureus. After dilution to a concentration of 106 CFU/ml, 10ml of
the dilutions was incubated at 371C for 2 hours with HPLC fractions
of human sweat of four healthy volunteers (2 ml sweat of each was
fractionated) in a total volume of 30ml in 10 mM sodium phosphate
buffer (pH 7.0)/10 mM sodium chloride. After incubation, cells were
diluted 1:100 in 10 mM sodium phosphate buffer (pH 7.0) and 90ml of
the diluted bacterial suspension was plated in triplicate on blood agar.
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